Rebeccamycin

Production and biological activity of rebeccamycin, a novel antitumor agent: J.A. Bush, et al.; J. Antibiot. (Tokyo) 40, 668 (1987) | Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives: Y. Yamashita, at al.; Biochemisty 31, 12069 (1992) | DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin: C. Bailly, et al.; Biochemistry 36, 3917 (1997) | Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group: F. Anizon, et al.; J. Med. Chem. 40, 3456 (1997) | Calories from carbohydrates: energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition: C. Bailly, et al.; Chem. Biol. 6, 277 (1999) | Discovery of Antitumor Indolocarbazoles: Rebeccamycin, NSC 655649, and Fluoroindolocarbazoles: B.H. Long, et al.; Curr. Med. Chem. 2, 255 (2002) | Rebeccamycin derivatives as dual DNA-damaging agents and potent checkpoint kinase 1 inhibitor: C. Marminon, et al.; Mol Pharmacol 74, 1620-1629 (2008) | Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers: A. Dowlati, et al.; Cancer Chemother Pharmacol 65, 73-78 (2009) | New progress of researches in carbazole compounds: F. Zhang, et al.; Chinese J. Org. Chem. 30, 783 (2010) | Checkpoint Kinase 1 activation enhances intestinal epithelial barrier function via regulation of claudin-5 expression: A. Watari, et al.; PLoS One 11, e0145631/1 (2016) | Rebeccamycin attenuates TNF-a-induced intestinal epithelial barrier dysfunction by inhibiting myosin light chain kinase production: A. Watari, et al.; Cell. Physiol. Biochem. 41, 1924 (2017) | The antitumor antibiotic rebeccamycin-challenges and advanced approaches in production processes: K. Pommerehne, et al.; Appl. Microbiol. Biotechnol. 103, 3627 (2019)